Report cover image

Blood Pressure Monitoring Devices Market Size, Share & Trends Analysis Report By Device Type (Non-Smart/Traditional Type, Smart Type), By End-use (Hospitals, Homecare, Ambulatory Surgery Centers & Clinics), By Region, And Segment Forecasts, 2026 - 2033

Publisher Grand View Research
Published Dec 22, 2025
Length 120 Pages
SKU # GV20723881

Description

Blood Pressure Monitoring Devices Market Summary

The global blood pressure monitoring devices market size was estimated at USD 4.19 billion in 2025 and is expected to reach USD 8.56 billion by 2033, growing at a CAGR of 9.34% from 2026 to 2033. The market expansion can be attributed to the increasing incidence of hypertension due to changing lifestyles.

Global Blood Pressure Monitoring Devices Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global blood pressure monitoring devices market report based on device type, connectivity, end use, and region:
  • Device Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Non-Smart/Traditional Type
  • Sphygmomanometer/Aneroid BP Monitor
  • Automated/Digital Blood Pressure Monitor
  • Upper Arm-based Traditional BP Monitors
  • Wrist-based Traditional BP Monitors
  • Finger-based Traditional BP Monitors
  • Ambulatory Blood Pressure Monitor
  • Smart Type
  • Upper Arm-based Smart BP Monitors
  • Wrist-based Smart BP Monitors
  • Finger-based Smart BP Monitors
  • Connectivity Outlook (Revenue, USD Million, 2021 - 2033)
  • Non-Connected
  • Connected
  • Wi-Fi-based
  • Bluetooth-based
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals
  • Ambulatory Surgery Centers & Clinics
  • Homecare
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Thailand
  • Latin America
  • Brazil
  • Argentina
  • Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
Please note The report will be delivered in 2-3 business days upon order notification.

Table of Contents

120 Pages
Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.1.1. Segment Definitions
1.1.1.1. Type
1.1.1.2. Technology Segment
1.1.1.3. Age Group Segment
1.1.1.4. Sector Type Segment
1.1.1.5. Distribution Channel Segment
1.1.1.6. End-use Segment
1.2. Regional Scope
1.3. Estimates and Forecast Timeline
1.4. Objectives
1.4.1. Objective - 1
1.4.2. Objective - 2
1.4.3. Objective - 3
1.5. Research Methodology
1.6. Information Procurement
1.6.1. Purchased Database
1.6.2. GVR’s Internal Database
1.6.3. Secondary Sources
1.6.4. Primary Research
1.7. Information or Data Analysis
1.7.1. Data Analysis Models
1.8. Market Formulation & Validation
1.9. Model Details
1.9.1. Commodity Flow Analysis
1.10. List of Secondary Sources
1.11. List of Abbreviations
Chapter 2. Rapid point-of-care testing for sickle cell anemia market: Executive Summary
2.1. Market Snapshot
2.2. Type
2.3. Technology Snapshot
2.4. Age Group Snapshot
2.5. Sector Type Snapshot
2.6. Distribution Channel Snapshot
2.7. End-use Snapshot
2.8. Competitive Landscape Snapshot
Chapter 3. Rapid point-of-care testing for sickle cell anemia market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Dynamics
3.4. Market Drivers Analysis
3.4.1. Rising demand for personalized medicine and genomic research
3.4.2. Growing prevalence of sickle cell disease (SCD)
3.4.3. Advancements in diagnostic technology
3.4.4. Government and NGO initiatives for early point-of-care (POC) screening
3.5. Market Restraint Analysis
3.5.1. Limited accessibility to advanced technologies
3.6. Porter’s Five Forces Analysis
3.7. PESTLE Analysis
3.8. Pipeline Analysis
Chapter 4. Rapid point-of-care testing for sickle cell anemia market: Type Estimates & Trend Analysis
4.1. Rapid point-of-care testing for sickle cell anemia market: Type Movement Analysis
4.2. Lateral flow immunoassay
4.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.3. Paper-based rapid diagnostics
4.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4. Others
4.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 5. Rapid point-of-care testing for sickle cell anemia market: Technology Estimates & Trend Analysis
5.1. Rapid point-of-care testing for sickle cell anemia market: Technology Movement Analysis
5.2. Hemoglobin electrophoresis
5.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.3. Polymerase chain reaction (PCR)
5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.4. Isothermal amplification assays
5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5. Others
5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 6. Rapid point-of-care testing for sickle cell anemia market: Age Group Estimates & Trend Analysis
6.1. Rapid point-of-care testing for sickle cell anemia market: Age Group Movement Analysis
6.2. Newborn screening (12 months and below)
6.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.3. Adult screening (25 to 60 years)
6.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4. Other age groups (1 to 25 & above 60 years)
6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 7. Rapid point-of-care testing for sickle cell anemia market: Sector Type Estimates & Trend Analysis
7.1. Rapid point-of-care testing for sickle cell anemia market: Sector Type Movement Analysis
7.2. Government labs
7.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
7.3. Private labs
7.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
7.4. Corporate labs
7.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5. PPP (public-private-partnerships)
7.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 8. Rapid point-of-care testing for sickle cell anemia market: Distribution Channel Estimates & Trend Analysis
8.1. Rapid point-of-care testing for sickle cell anemia market: Distribution Channel Movement Analysis
8.2. B2B (business-to-business)
8.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
8.3. B2C (business-to-consumer)
8.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 9. Rapid point-of-care testing for sickle cell anemia market: End use Estimates & Trend Analysis
9.1. Rapid point-of-care testing for sickle cell anemia market: End-use Movement Analysis
9.2. Hospitals & clinics
9.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
9.3. Diagnostics laboratories
9.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
9.4. Research institutions
9.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
9.5. Homecare settings
9.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
9.6. Others
9.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 10. Rapid point-of-care testing for sickle cell anemia market: Regional Business Analysis
10.1. Regional Market Snapshot
10.2. North America
10.2.1. North America Rapid point-of-care testing for sickle cell anemia market Estimates and Forecast, 2021 - 2033 (USD Million)
10.2.2. U.S.
10.2.2.1. Key Country Dynamics
10.2.2.2. Competitive Scenario
10.2.2.3. Regulatory Framework
10.2.2.4. Reimbursement Scenario
10.2.2.5. U.S. Rapid point-of-care testing for sickle cell anemia market, 2021 - 2033 (USD Million)
10.2.3. Canada
10.2.3.1. Key Country Dynamics
10.2.3.2. Competitive Scenario
10.2.3.3. Regulatory Framework
10.2.3.4. Reimbursement Scenario
10.2.3.5. Canada Rapid point-of-care testing for sickle cell anemia market, 2021 - 2033 (USD Million)
10.2.4. Mexico
10.2.4.1. Key Country Dynamics
10.2.4.2. Competitive Scenario
10.2.4.3. Regulatory Framework
10.2.4.4. Reimbursement Scenario
10.2.4.5. Mexico Rapid point-of-care testing for sickle cell anemia market, 2021 - 2033 (USD Million)
10.3. Europe
10.3.1. Europe Rapid point-of-care testing for sickle cell anemia market, 2021 - 2033 (USD Million)
10.3.2. UK
10.3.2.1. Key Country Dynamics
10.3.2.2. Competitive Scenario
10.3.2.3. Regulatory Framework
10.3.2.4. Reimbursement Scenario
10.3.2.5. UK Rapid point-of-care testing for sickle cell anemia market, 2021 - 2033 (USD Million)
10.3.3. Germany
10.3.3.1. Key Country Dynamics
10.3.3.2. Competitive Scenario
10.3.3.3. Regulatory Framework
10.3.3.4. Reimbursement Scenario
10.3.3.5. Germany Rapid point-of-care testing for sickle cell anemia market, 2021 - 2033 (USD Million)
10.3.4. Spain
10.3.4.1. Key Country Dynamics
10.3.4.2. Competitive Scenario
10.3.4.3. Regulatory Framework
10.3.4.4. Reimbursement Scenario
10.3.4.5. Spain Rapid point-of-care testing for sickle cell anemia market, 2021 - 2033 (USD Million)
10.3.5. France
10.3.5.1. Key Country Dynamics
10.3.5.2. Competitive Scenario
10.3.5.3. Regulatory Framework
10.3.5.4. Reimbursement Scenario
10.3.5.5. France Rapid point-of-care testing for sickle cell anemia market, 2021 - 2033 (USD Million)
10.3.6. Italy
10.3.6.1. Key Country Dynamics
10.3.6.2. Competitive Scenario
10.3.6.3. Regulatory Framework
10.3.6.4. Reimbursement Scenario
10.3.6.5. Italy Rapid point-of-care testing for sickle cell anemia market, 2021 - 2033 (USD Million)
10.3.7. Denmark
10.3.7.1. Key Country Dynamics
10.3.7.2. Competitive Scenario
10.3.7.3. Regulatory Framework
10.3.7.4. Reimbursement Scenario
10.3.7.5. Denmark Rapid point-of-care testing for sickle cell anemia market, 2021 - 2033 (USD Million)
10.3.8. Sweden
10.3.8.1. Key Country Dynamics
10.3.8.2. Competitive Scenario
10.3.8.3. Regulatory Framework
10.3.8.4. Reimbursement Scenario
10.3.8.5. Sweden Rapid point-of-care testing for sickle cell anemia market, 2021 - 2033 (USD Million)
10.3.9. Norway
10.3.9.1. Key Country Dynamics
10.3.9.2. Competitive Scenario
10.3.9.3. Regulatory Framework
10.3.9.4. Reimbursement Scenario
10.3.9.5. Norway Rapid point-of-care testing for sickle cell anemia market, 2021 - 2033 (USD Million)
10.4. Asia Pacific
10.4.1. Asia-Pacific Rapid point-of-care testing for sickle cell anemia market, 2021 - 2033 (USD Million)
10.4.2. Japan
10.4.2.1. Key Country Dynamics
10.4.2.2. Competitive Scenario
10.4.2.3. Regulatory Framework
10.4.2.4. Reimbursement Scenario
10.4.2.5. Japan Rapid point-of-care testing for sickle cell anemia market, 2021 - 2033 (USD Million)
10.4.3. China
10.4.3.1. Key Country Dynamics
10.4.3.2. Competitive Scenario
10.4.3.3. Regulatory Framework
10.4.3.4. Reimbursement Scenario
10.4.3.5. China Rapid point-of-care testing for sickle cell anemia market, 2021 - 2033 (USD Million)
10.4.4. India
10.4.4.1. Key Country Dynamics
10.4.4.2. Competitive Scenario
10.4.4.3. Regulatory Framework
10.4.4.4. Reimbursement Scenario
10.4.4.5. India Rapid point-of-care testing for sickle cell anemia market, 2021 - 2033 (USD Million)
10.4.5. South Korea
10.4.5.1. Key Country Dynamics
10.4.5.2. Competitive Scenario
10.4.5.3. Regulatory Framework
10.4.5.4. Reimbursement Scenario
10.4.5.5. South Korea Rapid point-of-care testing for sickle cell anemia market, 2021 - 2033 (USD Million)
10.4.6. Thailand
10.4.6.1. Key Country Dynamics
10.4.6.2. Competitive Scenario
10.4.6.3. Regulatory Framework
10.4.6.4. Reimbursement Scenario
10.4.6.5. Thailand Rapid point-of-care testing for sickle cell anemia market, 2021 - 2033 (USD Million)
10.4.7. Australia
10.4.7.1. Key Country Dynamics
10.4.7.2. Competitive Scenario
10.4.7.3. Regulatory Framework
10.4.7.4. Reimbursement Scenario
10.4.7.5. Australia Rapid point-of-care testing for sickle cell anemia market, 2021 - 2033 (USD Million)
10.5. Latin America
10.5.1. Latin America Rapid point-of-care testing for sickle cell anemia market, 2021 - 2033 (USD Million)
10.5.2. Brazil
10.5.2.1. Key Country Dynamics
10.5.2.2. Regulatory Framework
10.5.2.3. Reimbursement Scenario
10.5.2.4. Competitive Scenario
10.5.2.5. Brazil Rapid point-of-care testing for sickle cell anemia market, 2021 - 2033 (USD Million)
10.5.3. Argentina
10.5.3.1. Key Country Dynamics
10.5.3.2. Regulatory Framework
10.5.3.3. Reimbursement Scenario
10.5.3.4. Competitive Scenario
10.5.3.5. Argentina Rapid point-of-care testing for sickle cell anemia market, 2021 - 2033 (USD Million)
10.6. MEA
10.6.1. MEA Rapid point-of-care testing for sickle cell anemia market, 2021 - 2033 (USD Million)
10.6.2. South Africa
10.6.2.1. Key Country Dynamics
10.6.2.2. Regulatory Framework
10.6.2.3. Reimbursement Scenario
10.6.2.4. Competitive Scenario
10.6.2.5. South Africa Rapid point-of-care testing for sickle cell anemia market, 2021 - 2033 (USD Million)
10.6.3. Saudi Arabia
10.6.3.1. Key Country Dynamics
10.6.3.2. Regulatory Framework
10.6.3.3. Reimbursement Scenario
10.6.3.4. Competitive Scenario
10.6.3.5. Saudi Arabia Rapid point-of-care testing for sickle cell anemia market, 2021 - 2033 (USD Million)
10.6.4. UAE
10.6.4.1. Key Country Dynamics
10.6.4.2. Regulatory Framework
10.6.4.3. Reimbursement Scenario
10.6.4.4. Competitive Scenario
10.6.4.5. UAE Rapid point-of-care testing for sickle cell anemia market, 2021 - 2033 (USD Million)
10.6.5. Kuwait
10.6.5.1. Key Country Dynamics
10.6.5.2. Regulatory Framework
10.6.5.3. Reimbursement Scenario
10.6.5.4. Competitive Scenario
10.6.5.5. Kuwait Rapid point-of-care testing for sickle cell anemia market, 2021 - 2033 (USD Million)
Chapter 11. Competitive Landscape
11.1. Company Categorization
11.2. Strategy Mapping
11.2.1. New Product Launch
11.2.2. Partnerships
11.2.3. Acquisition
11.2.4. Collaboration
11.2.5. Funding
11.3. Key Company Market Share Analysis, 2025
11.4. Company Heat Map Analysis
11.5. Company Profiles
11.5.1. BIOMEDOMICS INC.
11.5.1.1. Company Overview
11.5.1.2. Financial Performance
11.5.1.3. Product Benchmarking
11.5.1.4. Strategic Initiatives
11.5.2. Silver Lake Research Corporation
11.5.2.1. Company Overview
11.5.2.2. Financial Performance
11.5.2.3. Product Benchmarking
11.5.2.4. Strategic Initiatives
11.5.3. Bio-Rad Laboratories, Inc.
11.5.3.1. Company Overview
11.5.3.2. Financial Performance
11.5.3.3. Product Benchmarking
11.5.3.4. Strategic Initiatives
11.5.4. Trivitron Healthcare
11.5.4.1. Company Overview
11.5.4.2. Financial Performance
11.5.4.3. Product Benchmarking
11.5.4.4. Strategic Initiatives
11.5.5. Hemex Health
11.5.5.1. Company Overview
11.5.5.2. Financial Performance
11.5.5.3. Product Benchmarking
11.5.5.4. Strategic Initiatives
11.5.6. Sysmex Corporation
11.5.6.1. Company Overview
11.5.6.2. Financial Performance
11.5.6.3. Product Benchmarking
11.5.6.4. Strategic Initiatives
11.5.7. EKF Diagnostics Holding plc.
11.5.7.1. Company Overview
11.5.7.2. Financial Performance
11.5.7.3. Product Benchmarking
11.5.7.4. Strategic Initiatives
11.5.8. HemoCie America (Danaher)
11.5.8.1. Company Overview
11.5.8.2. Financial Performance
11.5.8.3. Product Benchmarking
11.5.8.4. Strategic Initiatives
11.5.9. Transasia Bio-Medicals
11.5.9.1. Company Overview
11.5.9.2. Financial Performance
11.5.9.3. Product Benchmarking
11.5.9.4. Strategic Initiatives
11.5.10. Mylab Discovery Solutions
11.5.10.1. Company Overview
11.5.10.2. Financial Performance
11.5.10.3. Product Benchmarking
11.5.10.4. Strategic Initiatives
11.5.11. Biogenix Inc.
11.5.11.1. Company Overview
11.5.11.2. Financial Performance
11.5.11.3. Product Benchmarking
11.5.11.4. Strategic Initiatives
11.5.12. HALCYON Biomedical Incorporated
11.5.12.1. Company Overview
11.5.12.2. Financial Performance
11.5.12.3. Product Benchmarking
11.5.12.4. Strategic Initiatives

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us